About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Ohio | 757 Studies

Clinical Trials LymphomaOhio

Lymphoma Clinical Trials in Ohio

Find 757 clinical trials for lymphoma near Ohio. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 501-520 of 757 trials

Active not recruitingBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK…NCT02568267·Phoenix, Arizona and 119 others

PreviousPage 26 of 38Next

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedPhase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersThis study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in…NCT04553692·Phoenix, Arizona and 57 others

CompletedStudy of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaThis phase I clinical trial studies the side effects and the best dose of phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 when given together with rituximab in treating…NCT02049541·Atlanta, Georgia and 1 other

CompletedEfficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative TherapyThe purpose of this study is to determine the efficacy and safety of transplanting StemEx® in patients with certain hematological malignancies.NCT00469729·Los Angeles, California and 29 others

WithdrawnA Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)This randomized, open-label, multicenter study will evaluate the efficacy and safety of navitoclax in addition to bendamustine and rituximab in patients with relapsed diffuse…NCT01423539·Fountain Valley, California and 12 others

RecruitingCC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaThis phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell…NCT06209619·Columbus, Ohio

Active not recruitingA Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.NCT04245839·Santa Monica, California and 48 others

CompletedSafety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaThe purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic…NCT01109069·Stanford, California and 15 others

CompletedA Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded…NCT05144841·Orange, California and 70 others

CompletedThe Second Multicenter Hemophilia Cohort StudyThe Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus…NCT00341705·Tucson, Arizona and 47 others

Approved for marketingStudy of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesThe primary objectives of this study are: Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell…NCT04162756·Stanford, California and 8 others

CompletedQuality of Life in Younger Leukemia and Lymphoma SurvivorsRATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best…NCT00956475·Cleveland, Ohio

CompletedLiposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00006383·Los Angeles, California and 8 others

TerminatedA Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaThis study is about a medicine called TAK-981 given with rituximab, used to treat adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma. This study has 2 parts.NCT04074330·Birmingham, Alabama and 58 others

CompletedCPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersThis is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in…NCT03454451·Tucson, Arizona and 26 others

CompletedCombination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00005601·Scottsdale, Arizona and 20 others

TerminatedA Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter SyndromeDetermine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in…NCT04978779·Cincinnati, Ohio and 4 others

Active not recruitingFirst-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaThe purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™…NCT03625037·Phoenix, Arizona and 84 others

CompletedClinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaThe purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute…NCT01471782·Aurora, Colorado and 29 others

RecruitingTesting the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaThis phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated…NCT04840602·Tucson, Arizona and 144 others

Other Conditions in Ohio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia